Document:

EX-10.7

 Exhibit 10.7 

EXECUTION VERSION 
 KENNEDY
LEWIS INVESTMENT MANAGEMENT LLC 
 February 26, 2021 

Eastman Kodak Company 
 343 State Street 

Rochester, New York 14650 
 Re: Board Rights 

Ladies and Gentlemen: 
 Reference is made to that
certain Credit Agreement, dated as of the date hereof (the “Credit Agreement”), by and among Eastman Kodak Company, a New Jersey corporation (“Company”), the other Loan Parties party thereto, the lenders from time
to time party thereto (the “Lenders”) and Alter Domus (US) LLC, as administrative agent (in such capacity, the “Administrative Agent”). Capitalized terms used but not defined herein shall have the meanings ascribed
to such terms in the Credit Agreement. 
 In connection with the execution and delivery of the Credit Agreement, Company and Kennedy Lewis
Investment Management LLC (together with its affiliates and certain funds, accounts or clients managed, advised or sub-advised by Kennedy Lewis Investment Management LLC or its affiliates,
“KLIM”) (each, a “Party,” and, together, the “Parties”) desire to enter into this letter agreement (this “Agreement”) to define certain rights and obligations of the Parties,
including, without limitation, certain rights that KLIM shall have with respect to the board of directors (or similar governing body) of Company (the “Board”) or its successors or assigns, to be exercised by the individuals
designated by KLIM in accordance with the terms set forth herein. In consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree, intending to
be legally bound, as follows: 
 1. Board Nomination Right. 

(a) As soon as practicable after the date hereof, and in any event on or prior to the next annual meeting of the Company’s shareholders,
the Company agrees that the Board will appoint Darren L. Richman as a member of the Board, provided that as a condition to such appointment, Mr. Richman will have satisfied all applicable requirements regarding service as a director of
the Company under applicable law or stock exchange rules regarding service as a director and such other criteria and qualifications for service as a director applicable to all directors of the Company and in effect from time to time. Thereafter,
until the earlier of (i) the third anniversary of the date hereof or (ii) such time as KLIM ceases to hold at least 50% of the original principal amount of the Loans and Commitments in respect of the Credit Agreement that were outstanding
as of the Closing Date, KLIM shall be entitled to, at each annual or special meeting of the Company’s shareholders during such period, nominate one (1) director (such Person, which shall be Mr. Richman to the extent he is appointed to
the Board prior to the next annual meeting of the Company’s shareholders, the “Designated Director”) to serve on the Board; provided, however, that such nomination is subject to such Designated Director’s
satisfaction of all applicable requirements regarding service as a director of the Company under applicable law or stock 

 
exchange rules regarding service as a director and such other criteria and qualifications for service as a director applicable to all directors of the Company and in effect from time to time. In
the event that a Designated Director is nominated, the Company shall (i) include such Designated Director in its slate of nominees for election to the Board at each annual or special meeting of the Company’s shareholders,
(ii) recommend that the Company’s shareholders vote in favor of the election of the Designated Director and (iii) support the Designated Director in a manner generally no less rigorous and favorable than the manner in which the
Company supports its other Board nominees. The Company shall take all reasonably necessary actions to ensure that, at all times when a Designated Director is eligible to be appointed or nominated, there are sufficient vacancies on the Board to
permit such designation. Notwithstanding the foregoing, the rights of KLIM to appoint or nominate one (1) director shall terminate immediately on the earlier of (A) the third anniversary of the date hereof or (B) such time as KLIM
ceases to hold at least 50% of the original principal amount of the Loans and Commitments in respect of the Credit Agreement that were outstanding as of the Closing Date. 

(b) If any Designated Director ceases to serve on the Board for any reason during his or her term, the vacancy created thereby shall be
filled, and the Company shall cause the Board to fill such vacancy, with a new Designated Director eligible to serve on the Board in accordance with Section 1(a); provided, however, notwithstanding anything to the contrary in this Agreement, in
the event that KLIM’s rights under Section 1(a) have been terminated pursuant to the terms of this Agreement, any Designated Director serving on the Board at such time shall immediately tender his or her resignation; provided further that
(i) such requirement may be waived in advance by the Company’s Compensation, Nominating & Governance Committee and (ii) such resignation shall be subject to the approval of the Board. 

(c) For the avoidance of doubt, a Designated Director shall be entitled to the same retainer, equity compensation and other fees or
compensation, including travel and expense reimbursement, paid to the non-executive directors of the Company for his or her service as a director, and the Company shall maintain, in full force and effect,
directors’ and officers’ liability insurance in reasonable amounts to the same extent it now indemnifies and provides insurance for the non-executive directors on the Board. Any director minimum
share ownership requirements shall be deemed satisfied in respect of the Designated Director by any shares (or notes convertible into shares) of common stock held by KLIM or one or more of its Affiliates. The Company acknowledges and agrees that it
is the indemnitor of first resort (for the Designated Director in connection with matters arising from Designated Director’s service as a director of the Company). For the avoidance of doubt, the Designated Director shall be entitled to
customary access and information rights in the same manner as received by the other directors on the Board. 
 2. Board Observation
Rights. 
 (a) Until such time as KLIM ceases to hold at least 50% of the original principal amount of the Loans and Commitments in
respect of the Credit Agreement that were outstanding as of the Closing Date, and solely to the extent that a Designated Director is not serving on the Board at the applicable time, KLIM shall have the right to designate (i) one observer who is
a natural person reasonably acceptable to the Company (the “Observer Representative”) and (ii) one alternate observer who is a natural person reasonably acceptable to the Company (the “Alternate Observer”, and
together with the Observer Representative, collectively, the 

  
 2 

 
“Observer”) one of whom shall have the right to be present (whether in person or by telephone) in a non-voting observer capacity at all
meetings of the Board and each current or future committee and subcommittee thereof to the extent that (I) the Board has delegated substantially all of its functions to such committee or subcommittee or (II) such committee or subcommittee
has been delegated authority by the Board to consider a strategic transaction (but solely to the extent the meetings or materials of such committee or subcommittee relate to such strategic transaction) (as applicable, the “Relevant
Body”). The Alternate Observer shall have the same rights as the Observer Representative in the event that the Observer Representative is unable to exercise his or her rights as set forth herein or as otherwise notified by KLIM to the
Company in writing. At any time and from time to time while this Agreement is in effect, such Observer may be removed or replaced by KLIM in its sole discretion with a natural person reasonably acceptable to the Company, provided that, without the
consent of the Company (not to be unreasonably withheld, delayed or conditioned), such replacement shall not occur more than once in any 12-month period except in the case of an Observer ceasing to be an
employee or consultant of KLIM, and the term “Observer” in this Agreement shall also refer to any such replacement designee. Notwithstanding the foregoing, KLIM shall not be entitled to any observation rights under Section 2 hereof at
any time when a Designated Director is serving on the Board pursuant to Section 1. 
 (b) The Observer shall be entitled to
(i) attend and, subject to the limitations set forth in Section 2(c), participate (in person, telephonically, or by such other means as is available to any members of the Relevant Body in connection with such meetings or in accordance with
the terms herein) all meetings of the Relevant Body (whether regular or special, formal or informal) (a “Relevant Body Meeting”), (ii) receive written notice of, and agendas and attendance details for, all Relevant Body Meetings
(including minutes of previous meetings) substantially simultaneously with all other members of the Relevant Body prior to such Relevant Body Meetings, and (iii) if the Relevant Body proposes to take any action by written consent in lieu of a
meeting or otherwise act other than at a Relevant Body Meeting, receive a copy of such written consent when sent to some or all members of the Relevant Body for execution and (iv) receive all other documents (whether in draft or final form, and
including all exhibits, schedules and appendices thereto), notices, presentations, minutes, reports, consents, resolutions, written materials and other information provided to any members of the Relevant Body. The Observer shall not be entitled to
actively participate in any such meetings unless expressly invited to participate by the chairman of the Board and in any case shall be subject to the limitations set forth in Section 2(c). 

(c) With respect to the matters set forth in Section 2(b), the Observer may be excluded from any Relevant Body Meeting or portion of such
Relevant Body Meeting, or denied access to information or documentation, if the Relevant Body determines in good faith that (A) providing the Observer with access to such meeting or information may reasonably be expected to (i) adversely
affect attorney-client privilege from which such communication would otherwise benefit, (ii) give rise to an actual or potential conflict of interest between the Observer and/or KLIM, on the one hand, and Company or any of its Affiliates, on
the other; (iii) result in a breach of fiduciary duty of any Board member or (iv) result in a breach of confidentiality obligations to third parties or applicable law or (B) such Board Meeting or portion thereof or such information or
documentation includes or relates to materials of a sensitive or confidential nature (including for the avoidance of doubt, any matters of a proprietary nature, such as inventions, trade secrets and know-how
and any details or discussions regarding any potential or actual refinancing or restructuring plans); provided, however, that any such exclusion or denial of access shall be limited

  
 3 

 
to the portion of the information or documentation and/or meeting that is related to the basis for such exclusion or denial of access; provided, further, that in any event, KLIM
shall receive notice of (A) the occurrence of such meeting in accordance with Section 2(b) and a summary thereof and (B) the exclusion of such information and documentation and the basis and summary thereof (but not the substance
thereof). 
 (d) The Observer shall not be deemed a director of Company. For the avoidance of doubt, the Observer shall not (i) have
voting rights or the right to participate in any discussions (except as provided in Section 2(b) above) of or action by written consent of any Relevant Body, (ii) have the right to call special meetings of any Relevant Body, or
(iii) be counted for purposes of determining the size of any Relevant Body or whether a quorum has been obtained. The Observer shall not, by virtue of his or her capacity as such, have or be deemed to have, or otherwise be subject to, any
duties (fiduciary or otherwise) to the Company or its Subsidiaries or its or their equityholders or any other person or entity or any duties (fiduciary or otherwise) otherwise applicable to the members of the Relevant Body. 

(e) The Company shall pay the Observer’s reasonable
out-of-pocket expenses in connection with each Observer’s in-person attendance at such Relevant Body Meetings, subject to
the same expense limitations that are applicable to members of the Relevant Body under the Company’s travel policies. 
 3.
Indemnification. 
 (a) A Designated Director shall be entitled to the same indemnification rights as other non-executive directors of the Company. 
 (b) The Company shall indemnify and hold harmless the Observer
from and against any and all losses, claims, causes of action, damages, liabilities and expenses, including attorney’s fees (collectively, “Losses”), to which the Observer may become subject, insofar as such Losses (or
actions in respect thereof) arise out of, relate to, or are based upon the Observer’s (i) designation or attendance as a non-voting observer at any Relevant Body Meeting, (ii) receipt of
materials, consents or information under this Agreement, or (iii) exercise of his or her rights under this Agreement; provided that the Company shall have no obligation to indemnify any Observer from any claims arising from (x) a
breach of this Agreement or of the Credit Agreement by such Observer, KLIM or any of its Affiliates, or (y) any dispute between any Lenders under the Credit Agreement not arising as a result of a default by the Company or its Subsidiaries
thereunder. The Company will pay or reimburse the Observer for such Losses as they are incurred, including, without limitation, for amounts incurred in connection with investigating or defending any such Loss or action in respect thereof. 

(c) Promptly after receipt by the Observer of notice of the commencement of any action, the Observer will, if a claim in respect thereof is to
be made under this Section 3, notify the Company in writing of the commencement thereof, but the delay or omission to so notify the Company will not relieve the Company from any liability under this Section 3. In case any such action is
brought against the Observer, and the Observer notifies the Company of the commencement thereof, the Company will be entitled, at its sole discretion, to assume the defense thereof, with separate counsel, at its sole cost and expense. Such
assumption shall not relieve the 

  
 4 

 
Company of the obligation to pay or reimburse the Observer for reasonable and documented out-of-pocket legal and
other expenses incurred by the Observer in defending himself or herself. Subject to the limitations set forth herein, the Company shall pay all reasonable and documented legal fees and expenses of the Observer (limited to the fees and expenses of
one firm of counsel for KLIM, the Observer and their Affiliates collectively) in the defense of such claims or actions. In addition to, and notwithstanding the foregoing, the Observer shall be entitled to all rights to indemnification and
exculpation, to the same extent and in the same manner, as are made available to any other member of the applicable Relevant Body as of the date hereof, together with any and all incremental rights added thereto following the date hereof. 

4. Confidentiality. 
 (a)
A Designated Director shall be bound by the same confidentiality restrictions as the other non-executive directors; provided that a Designated Director may provide information concerning or relating to
the Company or any of its subsidiaries that is furnished to the Designated Director in his or her capacity as such, to KLIM and its representatives (provided that any such disclosure is pursuant to a confidentiality agreement between the Company and
KLIM in form and substance reasonably acceptable to each of the Company and KLIM (which shall provide that KLIM shall be subject to the Company’s trading policy to the same extent as a director of the Company in the event KLIM receives
confidential information from a Designated Director (and which shall not include any mandatory disclosure requirements for the Company)), but shall not provide any such information to the extent the chairman of the Board determines that providing
such information to KLIM and its representatives would reasonably be expected to (i) adversely affect attorney-client privilege from which such information would otherwise benefit or (ii) result in a breach of confidentiality obligations
to third parties or applicable law and has informed the Designated Director of such determination; provided, further, that the Designated Director shall recuse himself or herself, as applicable, from any Board meeting or portion
thereof in the event such meeting relates to any potential or actual financing, refinancing or restructuring involving the Company or if the Designated Director’s participation otherwise would, in the judgment of the chairman of the Board, give
rise to an actual or potential conflict of interest between the Designated Director and/or KLIM, on the one hand, and the Company or any of its Affiliates, on the other. 

(b) Company acknowledges and agrees that the Observer (but not a Designated Director) may, if and to the extent he or she desires to do so,
disclose to KLIM information, including certain confidential or proprietary information, concerning Company and/or any of its Subsidiaries that he or she obtains in his or her capacity as the Observer hereunder. Each Observer and KLIM, on behalf of
itself and each Observer, agrees that all information provided to or learned by the Observer in connection with the rights granted by Company under this Agreement shall be subject to the confidentiality provisions set forth in the Credit Agreement
(provided that any such information shall not be disclosed to any Lender that is not KLIM or an Affiliate of KLIM). 
 5. Insurance.
During the Term of this Agreement, and thereafter for the duration of the applicable statute of limitations: 
 (a) with respect to a
Designated Director, the Company shall maintain, in full force and effect, directors’ and officers’ liability insurance in reasonable amounts to the same extent it now indemnifies and provides insurance for the non-executive directors on the Board; and 

  
 5 

 (b) with respect to any Observer, the Company agrees to use commercially reasonable efforts
to provide for coverage of the Observer under the policies of officers’ and directors liability insurance that the Company maintains from time to time; provided, however, that nothing herein shall require the Company to incur any increased
premium or other costs or acquire any new insurance policies in order to extend such coverage to the Observer. 
 6. Term. This
Agreement shall be effective as of the date hereof and shall remain in full force and effect until the earlier to occur of the following: (i) KLIM and its Affiliates shall cease to retain beneficial ownership of and full voting rights with
respect to at least 50% of the original principal amount of the Loans and Commitments in respect of the Credit Agreement that were outstanding as of the Closing Date, and (ii) the date that the Commitments have expired or terminated and the
Obligations under the Credit Agreement and the other Loan Documents shall have been paid in full (other than contingent indemnification obligations not then due and owing) (the “Term”). Notwithstanding anything to the contrary
hereto, Sections 3, 4, 6, 8 and 12-17 shall survive any termination of this Agreement. 
 7. No
Assignment; Benefit of Parties; No Transfer. No Party may assign this Agreement or any of its rights or obligations hereunder without the prior written consent of the other Party, any such assignment being void ab initio; provided,
however, that KLIM (or its assignee) may assign this Agreement, in whole but not in part, without the prior written consent of Company to any Affiliate of KLIM, subject to such Affiliate acceding to and becoming party to this Agreement and
agreeing to be subject to the confidentiality provisions set out in the Credit Agreement; provided that such proposed assignee is not a bona fide direct competitor or a financial sponsor that directly or indirectly owns a direct competitor
identified in writing by Company to the Administrative Agent prior to the date hereof, as such list may be updated from time to time thereafter; provided, further, that Company may assign its rights hereunder to any successor entity or
in connection with the sale of all or substantially all its assets. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assigns for the uses and purposes set forth and
referred to herein. Each of the Parties acknowledges and agrees that the Designated Director and/or Observer is a third party beneficiary of this Agreement and is entitled to the rights and benefits hereunder and may enforce the provisions hereof as
if he or she were a party hereto. Except as explicitly set forth herein, nothing contained in this Agreement shall confer or is intended to confer on any third party or entity that is not a party hereto any rights under this Agreement. 

8. Remedies. Each of the Parties shall be entitled to enforce their rights under this Agreement specifically, to recover damages by
reason of any breach or violation of any provision of this Agreement and to exercise all other rights existing in their favor. The Parties agree and acknowledge that a breach or violation of this Agreement would cause irreparable harm and that money
damages would not be an adequate remedy for any such breach and that, in addition to other rights and remedies hereunder, each of the Parties shall be entitled to seek specific performance and/or injunctive or other equitable relief (without posting
a bond or other security) from any court of law or equity of competent jurisdiction in order to enforce or prevent any breaches or violations of this Agreement. 

  
 6 

 9. Representations and Warranties. Each Party hereby represents and warrants to the
other Party as follows: 
 (a) Such Party is duly incorporated, organized, or formed (as applicable), validly existing, and (if applicable)
in good standing under the laws of the jurisdiction of its incorporation, organization, or formation; if required by applicable law, that such Party is duly qualified and in good standing in the jurisdiction of its principal place of business, if
different from its jurisdiction of incorporation, organization, or formation; and that such Party has the requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder, and all necessary actions by the
board of directors (or similar governing body), officers, equityholders, managers, members, partners, trustees, beneficiaries, or other applicable persons necessary for the due authorization, execution, delivery, and performance of this Agreement by
such Party have been duly taken. 
 (b) Such Party has duly executed and delivered this Agreement, and (assuming the due execution and
delivery by each other Party hereto) this Agreement constitutes the valid and binding obligation of such Party enforceable against it in accordance with its terms (except as may be limited by applicable bankruptcy, insolvency or similar laws and by
the effect of general principles of equity, regardless of whether considered at law or in equity). 
 (c) Such Party’s authorization,
execution, delivery, and performance of this Agreement does not and will not (i) conflict with, or result in a breach, default or violation of, (A) the organizational documents of such Party, (B) any material contract or agreement to
which such Party is a party or is otherwise subject, or (C) any law, writ, injunction, or arbitral award to which such Party is subject; or (ii) require any consent, approval, or authorization from, filing or registration with, or notice
to, any governmental authority or other person (including the equityholders or any Relevant Body), unless such requirement has already been satisfied. 

10. Further Assurances. Each of the Parties hereby agrees that it will hereafter execute and deliver any further document, agreement,
instruments of assignment, transfer or conveyance as may be necessary or desirable to effectuate the purposes hereof (including the ability of KLIM to exercise observer rights in respect of any current or future Relevant Body). 

11. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of
which shall be deemed one instrument, and may be delivered by means of facsimile or electronic transmission in portable document format. 

12. Governing Law; Jurisdiction. This Agreement, and any matter or dispute arising out of or related to this Agreement, shall be
exclusively construed by, subject to and governed in accordance with the internal laws of the State of Delaware without giving effect to conflict of laws or other principles that may result in the application of laws other than the internal laws of
the State of Delaware. Unless each of the Parties consents in writing, the state and federal courts of Delaware shall, to the fullest extent permitted by applicable law, be the sole and exclusive forum for any legal action or proceeding arising out
of this Agreement. Each Party irrevocably consents to the service of process outside the territorial jurisdiction of such courts in any such action or proceeding in accordance with Section 17 of this Agreement, although nothing contained in
this Agreement shall affect the right to serve process in any other manner permitted by applicable law. Each Party (i) certifies that no representative, agent or attorney of any Party has represented, expressly or otherwise, that such Party
would not, in the event of litigation, seek to enforce that foregoing waiver and (ii) acknowledges that it and the other Parties have been induced to enter into this Agreement, as applicable, by, among other things, the mutual waivers and
certifications in this Section 12. 

  
 7 

 13. Mutual Waiver of Jury Trial. THE PARTIES HEREBY IRREVOCABLY WAIVE ANY AND ALL
RIGHTS TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT. ANY ACTION OR PROCEEDING WHATSOEVER BETWEEN THE PARTIES HERETO RELATING TO THIS AGREEMENT SHALL BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE
SITTING WITHOUT A JURY. 
 14. Severability. In the event that any one or more of the provisions herein should be held invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision
in a particular jurisdiction shall not affect the validity of such provision in any other jurisdiction). 
 15. Entire Agreement.
This Agreement (together with the Credit Agreement and the other Loan Documents) constitutes the entire agreement and understanding of the Parties in respect of the subject matter hereof and supersedes all prior understandings, agreements or
representations by or among the Parties, written or oral, to the extent they relate in any way to the subject matter hereof. 
 16.
Amendment; Waiver. No amendment of any provision of this Agreement shall be effective unless set forth in a written instrument executed by both Parties. Except as otherwise provided herein, no waiver of any provision of this Agreement shall
be effective unless set forth in a written instrument executed by the Party against whom the waiver is effective. The failure of any Party to enforce any provision hereof shall in no way be construed as a waiver of such provision or of any other
provision and shall not affect the right of such Party thereafter to enforce each and every provision hereof in accordance with its terms. The rights and remedies in this Agreement are cumulative and not exclusive of any rights or remedies provided
by law. 
 17. Notices. All notices, reports and other communications required by this Agreement must be written and sent, and shall
be deemed given, as provided in the Credit Agreement and, if applicable, this Agreement. 
 [SIGNATURE PAGE FOLLOWS] 

  
 8 

 IN WITNESS WHEREOF, the undersigned have duly executed this Agreement as of the date first
indicated above. 
  

			
	KENNEDY LEWIS INVESTMENT MANAGEMENT LLC
		
	By:	 	/s/ Anthony Pasqua
	Name:	 	Anthony Pasqua
	Title:	 	Authorized Signatory

 [Signature Page to Board Rights Agreement] 

 
			
	EASTMAN KODAK COMPANY
		
	By:	 	/s/ David E. Bullwinkle
	Name:	 	David E. Bullwinkle
	Title:	 	Chief Financial Officer and Senior Vice President

 [Signature Page to Board Rights Agreement]EX-10.8

 Exhibit 10.8 

EXECUTION VERSION 
 SECURITIES
PURCHASE AGREEMENT 
 This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of February 26,
2021, is entered into by and between Eastman Kodak Company, a New Jersey corporation (the “Company”), Kennedy Lewis Capital Partners Master Fund LP, a Delaware limited partnership (“Fund I”), and
Kennedy Lewis Capital Partners Master Fund II LP (“Fund II, and together with Fund I, each a “Buyer” and collectively, the “Buyers”). 

WHEREAS, simultaneously with the execution and delivery of this Agreement, the Company is entering into that certain Credit Agreement, by and
among the Company, the lenders party thereto and Alter Domus (US) LLC, as Administrative Agent (as defined therein) (the “Credit Agreement”); 

WHEREAS, the Company and the Buyers are executing and delivering this Agreement in reliance upon an exemption from securities registration
afforded by the Securities Act of 1933, and the rules and regulations promulgated by the United States Securities and Exchange Commission thereunder (the “Securities Act”); 

WHEREAS, the Company wishes to issue and sell to the Buyers, and the Buyers wish to purchase from the Company, an aggregate of 1,000,000
shares of common stock, par value $0.01 per share, of the Company (the “Common Stock”) on the terms and conditions stated in this Agreement; 

WHEREAS, the Company has authorized the issuance of one or more convertible promissory notes, in the aggregate original principal amount of
$25.0 million, substantially in the form attached hereto as Exhibit A (the “Notes”), which Notes shall be convertible into shares of Common Stock, upon the terms and subject to the limitations and conditions set
forth in such Notes; and 
 WHEREAS, the Company and the Buyers will execute and deliver, among other things, a Registration Rights
Agreement, substantially in the form attached hereto as Exhibit B (the “Registration Rights Agreement”), in connection with the purchase and sale of the Purchased Shares (as defined below) and the Purchased Notes
(as defined below). 
 WHEREAS, this Agreement, the Notes, the Registration Rights Agreement and all other certificates, documents,
agreements, resolutions and instruments delivered to any party under or in connection with this Agreement, as the same may be amended from time to time, are collectively referred to herein as the “Transaction Documents.” 

NOW, THEREFORE, the Company and the Buyers hereby agree as follows: 

1. PURCHASE AND SALE OF PURCHASED SHARES. 

(a) Purchase and Sale of the Common Stock. On the terms and subject to the conditions herein, at the Closing (as defined below), the
Company shall issue and sell to the Buyers, and the Buyers agree to purchase from the Company, 1,000,000 shares of Common Stock, free and clear of any liens and other encumbrances (other than restrictions arising under applicable securities laws),
which shall be allocated among the Buyers as set forth on Schedule I. The shares of Common Stock to be issued and sold by the Company to the Buyers pursuant to this Agreement are referred to as the “Purchased Shares.”

 (b) Purchase Price. Each Buyer shall pay $10.00 in cash for each Purchased Share to
be purchased by each Buyer at the Closing (the “Shares Purchase Price”), for an aggregate Purchase Price of $10,000,000 (the “Shares Aggregate Purchase Price”), with each Buyer being obligated to pay
the portion of the Shares Aggregate Purchase Price set forth opposite its name on Schedule I. 
 2. PURCHASE AND SALE OF THE
PURCHASED NOTES. 
 (a) Purchase and Sale of the Notes. On the terms and subject to the conditions herein, at the Closing, the
Company shall issue and sell to the Buyers, and the Buyers agree to purchase from the Company, the Notes, free and clear of any liens and other encumbrances (other than restrictions arising under applicable securities laws) which shall be allocated
among the Buyers as set forth on Schedule I. The Notes to be issued and sold by the Company to the Buyers pursuant to this Agreement are referred to as the “Purchased Notes.” 

(b) Purchase Price. Each Buyer shall pay $25,000,000 in cash for the Purchased Notes to be purchased by each Buyer at the Closing (the
“Notes Purchase Price”), for an aggregate Purchase Price of $25,000,000 (the “Notes Aggregate Purchase Price”), with each Buyer being obligated to pay the portion of the Notes Aggregate Purchase Price
set forth opposite its name on Schedule I. 
 3. CLOSING. 

(a) Closing Date. The closing (the “Closing”) of the purchase and sale of the Purchased Shares and the
Purchased Notes shall occur simultaneously with the execution and delivery of this Agreement, remotely by electronic exchange of Closing documentation. The date on which the Closing occurs is referred to as the “Closing Date.” 

(b) Closing. At the Closing, (i) each Buyer shall (A) pay its respective portion of the Shares Aggregate Purchase Price to
the Company for the Purchased Shares, by wire transfer of immediately available funds in accordance with the Company’s written wire instructions or as otherwise agreed to by the parties, (B) pay its respective portion of the Notes
Aggregate Purchase Price to the Company for the Purchased Notes, by wire transfer of immediately available funds in accordance with the Company’s written wire instructions or as otherwise agreed to by the parties, and (C) deliver to the
Company a duly executed copy of the Registration Rights Agreement and (ii) the Company shall (A) issue to each Buyer in book-entry form the Purchased Shares in the amounts set forth on Schedule I, (B) issue to each Buyer an
electronic copy of the physical Purchased Notes in the amounts set forth on Schedule I, and (C) deliver to each Buyer a duly executed copy of the Registration Rights Agreement. Within three (3) Business Days (as defined below) of
the Closing, the Company shall issue to each Buyer in physical form the Purchased Notes. For the purposes of this Section 3(b), “Business Days” shall mean any day other than a Saturday, Sunday or other day on which commercial banks in
New York, New York are authorized or required by law to remain closed. 

  
 2 

 4. BUYERS’ REPRESENTATIONS AND WARRANTIES. Each Buyer represents and warrants,
severally and not jointly, to the Company that as of the date hereof: 
 (a) Organization and Qualification. Such Buyer is duly
organized and validly existing and in good standing under the laws of the Cayman Islands and has the requisite power and authorization to carry on its business as now being conducted in all material respects. 

(b) Authorization; Validity; Enforcement. Such Buyer has the requisite power and authority to enter into and perform its obligations
under this Agreement and the Registration Rights Agreement. The execution and delivery of this Agreement and the Registration Rights Agreement by each Buyer and the consummation by such Buyer of the transactions contemplated hereby and thereby have
been duly authorized by such Buyer. This Agreement has been, and, when executed, the Registration Rights Agreement will be, duly and validly executed and delivered on behalf of each Buyer and constitutes the legal, valid and binding obligations of
each Buyer enforceable against each Buyer in accordance with its terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws
relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies, regardless of whether considered in a proceeding in equity or at law. 

(c) No Conflicts. The execution, delivery and performance by each Buyer of this Agreement and the Registration Rights Agreement and the
consummation by each Buyer of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of each Buyer, (ii) conflict with, or constitute a default (or an event which with notice or
lapse of time or both would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which each Buyer is a party, or (iii) result
in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and state securities laws and regulations and applicable laws of any foreign, federal, and other state laws) applicable to each Buyer or by which any
property or asset of each Buyer is bound or affected, other than, in the case of clause (ii) or clause (iii), as would not, individually or in the aggregate, reasonably be expected to prevent, materially delay, or materially impair the
Buyers’ ability to consummate any of the transactions contemplated hereby. 
 (d) Consents. Each Buyer is not required to obtain
any consent, authorization or order of, or make any filing or registration with any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver or perform any of its obligations
under or contemplated by this Agreement or the Registration Rights Agreement. 
 (e) Purchase for Investment. Each Buyer acknowledges
that as of the Closing Date the Purchased Shares, the Purchased Notes and the Conversion Shares (as defined below) will not have been registered under the Securities Act or under any state or other applicable securities laws. Each Buyer acknowledges
that it (i) is acquiring the Purchased Shares, the Purchased Notes and the Conversion Shares pursuant to an exemption from registration under the Securities Act solely for investment and for each Buyer’s own account, not as nominee or
agent, and with no present intention or view to distribute any of the Purchased Shares, the Purchased 

  
 3 

 
Notes and the Conversion Shares to any Person in violation of the Securities Act, (ii) will not sell or otherwise dispose of any of the Purchased Shares, the Purchased Notes and the
Conversion Shares, except in compliance with the registration requirements or exemption provisions of the Securities Act and any other applicable securities laws, (iii) is knowledgeable, sophisticated and experienced in financial and business
matters, has previously invested in securities similar to the Purchased Shares, the Purchased Notes and the Conversion Shares, understands the limitations on transfer and the restrictions on sales of such Purchased Shares, the Purchased Notes and
the Conversion Shares and is able to bear the economic risk of its investment and afford the complete loss of such investment, (iv) (A) has such knowledge and experience in financial and business matters and in investments of this type, that it
is capable of evaluating the merits and risks of its investment in the Purchased Shares, the Purchased Notes and the Conversion Shares and of making an informed investment decision, (B) has conducted an independent review and analysis of the
business and affairs of the Company and its subsidiaries that it considers sufficient and reasonable for purposes of making its investment in the Purchased Shares, the Purchased Notes and the Conversion Shares, (C) based thereon and on its own
knowledge, has formed an independent judgment concerning the advisability of the transactions contemplated by this Agreement, and (v) is an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D
promulgated under the Securities Act). 
 (f) Access to Information. Each Buyer has relied solely on its own independent
investigation in evaluating the Company and the value of the Purchased Shares and the Purchased Notes in determining to proceed with the transactions under this Agreement (the “Transactions”) and has not relied on any
assertions made by the Company or its Affiliates or any person acting on their behalf other than the representations and warranties of the Company expressly set forth herein. Each Buyer has undertaken such independent investigation of the Company as
each Buyer in its judgment believes is appropriate to make an informed decision in connection with the Transactions. Each Buyer understands the disadvantage to which it is subject on account of the disparity of information as between the Company and
the Buyers with respect to the business and financial performance of the Company. Each Buyer has access to all information that it believes to be necessary, sufficient or appropriate in connection with the Transactions. Each Buyer has undertaken
such independent investigation of the Company as in its judgment is appropriate to make an informed decision with respect to the Transactions, and has made its own decision to consummate the Transactions based on its own independent review and
consultations with such investment, legal, tax, accounting and other advisers as it has deemed necessary and without reliance on any express or implied representation or warranty of the Company (except as expressly set forth herein). Each Buyer
understands that the Company has and may come into possession of material non-public information with respect to the Company not known to each Buyer, including, without limitation, information with respect to
the Company’s financial performance for the year ended December 31, 2020. Each Buyer acknowledges that any such material non-public information not known to it may impact the value of the Company and
the Purchased Shares and the Purchased Notes or may otherwise be material to such the Buyers’ decision to enter into this Agreement and to consummate the Transactions. Each Buyer acknowledges that it is entering into this Agreement knowingly
and voluntarily, without access to or the benefit of such information. Each Buyer hereby waives any right to rescind or invalidate the issuance of the Purchased Shares and the Purchased Notes to the Buyers or to seek any damages or remuneration from
the Company based on the Company’s possession of any information regarding the Company or the lack of possession of any information regarding the Company by the Buyers. The foregoing does not limit or modify the representations and warranties
of the Company in Section 5 hereof or the right of the Buyers to rely thereon. 

  
 4 

 (g) Private Placement Consideration. Each Buyer understands and acknowledges that:
(i) its representations and warranties contained herein are being relied upon by the Company as a basis for availing itself of such exemption and other exemptions under the securities laws of all applicable states and for other purposes,
(ii) no U.S. state or federal agency has made any finding or determination as to the fairness of the terms of the sale of the Purchased Shares and the Purchased Notes or any recommendation or endorsement thereof, and (iii) the Purchased
Shares and the Purchased Notes are “restricted securities” under the Securities Act inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under applicable securities laws such
Purchased Shares and the Purchased Notes may be resold without registration under the Securities Act only in certain limited circumstances. 

(h) Ownership of Company Securities. Prior to the Closing, each Buyer does not have record or beneficial ownership (within the meaning
of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of any shares of Common Stock. 

(i) Brokers; Finders. No broker, investment banker, financial advisor or other Person is entitled to any broker’s, finder’s,
financial advisors or other similar fee or commission, or the reimbursement of expenses in connection therewith, in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of each Buyer. 

(j) No Other Company Representations or Warranties. Each Buyer acknowledges and agrees, on behalf of itself and its Affiliates, that,
except for the representations and warranties contained in Section 5, neither the Company nor any other Person, makes any express or implied representation or warranty with respect to the Company, its subsidiaries or their
respective businesses, operations, assets, liabilities, employees, employee benefit plans, conditions or prospects in connection with this Agreement (but specifically excluding the Credit Agreement), and each Buyer, on behalf of itself and its
Affiliates, hereby disclaims reliance upon any such other representations or warranties. In particular, without limiting the foregoing disclaimer, each Buyer acknowledges and agrees, on behalf of itself and its Affiliates, that neither the Company
nor any other Person, makes or has made any representation or warranty hereunder with respect to, and each Buyer, on behalf of itself and its Affiliates, hereby disclaims reliance upon (i) any financial projection, forecast, estimate, budget or
prospect information relating to the Company, its subsidiaries or their respective business, or (ii) without limiting the representations and warranties made by the Company in Section 5 (or under the Credit Agreement),
any information presented to each Buyer or any of its Affiliates or representatives in the course of their due diligence investigation of the Company, the negotiation of this Agreement or in the course of the transactions contemplated hereby. To the
fullest extent permitted by applicable law, without limiting the representations and warranties contained in Section 5 (and the representations and warranties of the Company under the Credit Agreement), neither the Company
nor any of its subsidiaries shall have any liability to each Buyer or its Affiliates or representatives on any basis (including in contract or tort, under federal or state securities laws or otherwise) based upon any other representation or
warranty, either express or implied, included in any information or statements (or any omissions therefrom) provided or made available by the Company or its subsidiaries to each Buyer or its Affiliates or representatives in the course of their due
diligence investigation of the Company, the negotiation of this Agreement or in the course of the transactions contemplated by this Agreement. 

  
 5 

 5. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants
to each Buyer as of the date hereof: 
 (a) Organization and Qualification. The Company is duly organized and validly existing and in
good standing under the laws of the State of New Jersey and has the requisite power and authority to carry on its business as now being conducted in all material respects. 

(b) Capitalization. Immediately prior to the Capitalization Date (as defined below), the authorized capital of the Company consists of
500,000,000 shares of Common Stock and 60,000,000 shares of preferred stock, no par value per share (“Preferred Stock”). As of the close of business on February 22, 2021 (the “Capitalization
Date”), there were 77,364,845 shares of Common Stock issued and outstanding, 2,000,000 shares of Preferred Stock designated as 5.5% Series A Convertible Preferred Stock issued and outstanding, and 711,791 shares of Common Stock held by
the Company as treasury shares. From the Capitalization Date through and as of the date of this Agreement, no other shares of Common Stock or Preferred Stock have been issued other than (i) Common Stock issued in respect of the exercise of the
Company’s stock options or grant or payment of Company stock awards in the ordinary course of business, (ii) the Common Stock issued pursuant to this Agreement, (iii) 1,000,000 shares of Preferred Stock designated as 4.0% Series B
Convertible Preferred Stock, and (iv) 750,000 shares (which shall be increased to 1,000,000 shares after the satisfaction of certain conditions and further increased by the number of such shares issued from time to time as dividends payable in kind
pursuant to the terms of such shares) of Preferred Stock designated as 5.0% Series C Convertible Preferred Stock. 
 (c) Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its obligations under the Transaction Documents and to consummate the transactions contemplated hereby and thereby and to issue the
Purchased Shares, the Purchased Notes and the Conversion Shares in accordance with the terms of this Agreement and the Purchased Notes. The execution and delivery of the Transaction Documents by the Company and the consummation by the Company of the
transactions contemplated hereby and thereby, including the issuance of the Purchased Shares, the Purchased Notes and the Conversion Shares (when issued pursuant to the terms of the Purchased Notes) have been duly authorized by the Company’s
Board of Directors (the “Board”) and no further consent or authorization is required by the Board, the Company or its shareholders. This Agreement has been, and, when executed, the Registration Rights Agreement, the Purchased
Notes and the other Transaction Documents will be, duly executed and delivered by the Company, and constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except
as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and
remedies, regardless of whether considered in a proceeding in equity or at law. 

  
 6 

 (d) Issuance of Purchased Shares. The issuance of the Purchased Shares is duly
authorized and, upon issuance in accordance with the terms of this Agreement, shall be (i) validly issued, (ii) free from all preemptive or similar rights, liens and other encumbrances with respect to the issue thereof (other than
restrictions arising under applicable securities laws) and (iii) fully paid and nonassessable, with the holder being entitled to all rights accorded to a holder of Common Stock. Assuming in part the accuracy of each of the representations and
warranties of the Buyers set forth in Section 4 of this Agreement, the offer and issuance by the Company of the Purchased Shares is exempt from registration under the Securities Act. 

(e) Issuance of Purchased Notes. The issuance of the Purchased Notes is duly authorized and, upon issuance in accordance with the terms
of this Agreement, shall be (i) validly issued, (ii) free from all preemptive or similar rights, liens and other encumbrances with respect to the issue thereof (other than restrictions arising under applicable securities laws) and
(iii) valid and binding obligations of the Company, with the holder being entitled to all rights accorded to a holder of the Purchased Notes. Assuming in part the accuracy of each of the representations and warranties of the Buyers set forth in
Section 4 of this Agreement, the offer and issuance by the Company of the Purchased Notes is exempt from registration under the Securities Act. 

(f) No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby (including the issuance of the Purchased Shares, the Purchased Notes and the Conversion Shares (when issued pursuant to the terms of the Purchased Notes)) will not (i) result in a
violation of the Company’s Certificate of Incorporation or the Company’s Bylaws, or (ii) conflict with, or constitute a default in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Company or any of its subsidiaries is a party, or (iii) assuming the accuracy of the representations and warranties of the Buyers under this Agreement, result in a violation of any law,
rule, regulation, order, judgment or decree applicable to the Company or any of its subsidiaries or by which any property or asset of the Company or any of its subsidiaries is bound or affected, other than, in the case of clause (ii) or clause
(iii), as would not, individually or in the aggregate, reasonably be expected to prevent, materially delay or materially impair the Company’s ability to consummate any of the transactions contemplated hereby. 

(g) Consents. The Company is not required to obtain any consent, authorization or order of, or make any filing or registration with
(other than the filing with the Securities and Exchange Commission of a Form D and one or more registration statements in accordance with the requirements of the Registration Rights Agreement, other filings as may be required by state
securities agencies and the listing of the Purchased Shares and the Conversion Shares on the New York Stock Exchange), any court, governmental agency or any regulatory or self-regulatory agency or any other Person in order for it to execute, deliver
or perform any of its obligations under or contemplated by the Transaction Documents, except (i) such as have been obtained or made and are in full force and effect and (ii) immaterial consents, approvals, registrations or filings. 

(h) No General Solicitation. Neither the Company, nor any of its subsidiaries, nor, to the knowledge of the Company, any Person acting
on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Purchased Shares, the Purchased Notes or the Conversion Shares.  

  
 7 

 (i) No Integrated Offering. None of the Company nor its subsidiaries, nor, to the
knowledge of the Company, any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the issuance
of any of the Purchased Shares under the Securities Act, whether through integration with prior offerings or otherwise, or cause this offering of the Purchased Shares, the Purchased Notes or the Conversion Shares to require the approval of the
shareholders of the Company for purposes of any applicable shareholder approval provisions, including under the rules and regulations of the New York Stock Exchange. 

(j) Conversion Shares. The Company understands and acknowledges that its obligations to issue all shares of Common Stock issuable upon
conversion of all or any portion of the Notes (the “Conversion Shares”) pursuant to the terms of the Notes in accordance with this Agreement and the Notes is absolute and unconditional regardless of the dilutive effect
that such issuance may have on the ownership interests of other shareholders of Company; when issued upon conversion of a Note in accordance with the terms of such Note, the Conversion Shares will be duly authorized, validly issued, fully paid for
and non-assessable, free of all preemptive or similar rights and free and clear of any security interest, mortgage, pledge, lien, claim, charge or other encumbrance of any kind (other than as may be granted by
each Buyer). 
 (k) No Other Buyer Representations or Warranties. The Company acknowledges and agrees, on behalf of itself and its
Affiliates, that, except for the representations and warranties contained in Section 4, neither the Buyers nor any other Person, makes any express or implied representation or warranty with respect to each Buyer, and the
Company, on behalf of itself and its Affiliates, hereby disclaims reliance upon any such other representations or warranties. To the fullest extent permitted by applicable law, without limiting the representations and warranties contained in
Section 4, neither the Buyers nor any of its Affiliates shall have any liability to the Company or its Affiliates or representatives on any basis (including in contract or tort, under federal or state securities laws or
otherwise) based upon any other representation or warranty, either express or implied, included in any information or statements (or any omissions therefrom) provided or made available by each Buyer or its Affiliates to the Company or its Affiliates
or representatives in the course the negotiation of this Agreement or the Registration Rights Agreement or in the course of the transactions contemplated by this Agreement or the Registration Rights Agreement. 

6. COVENANTS. 

(a) Legends. 
 (i) The
book-entry accounts maintained by the Company’s transfer agent representing the Purchased Shares, except as set forth below, shall bear a restrictive legend in substantially the following form: 

NEITHER THE ISSUANCE NOR SALE OF THESE SECURITIES HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) PURSUANT TO
AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933. 

  
 8 

 (ii) At the request of a holder of the Purchased Shares or Conversion Shares, upon receipt
of customary representations and opinions (to the extent reasonably required by the Company or the Company’s transfer agent), the legend set forth in Section 6(a)(i) above shall be removed from the applicable Purchased
Shares or Conversion Shares on the book-entry accounts maintained by the Company’s transfer agent representing the Purchased Shares or Conversion Shares if such legend is not required in order to establish compliance with any provisions of the
Securities Act. 
 (b) NYSE Listing. Promptly following the execution of this Agreement, the Company shall apply to cause the
Purchased Shares and the Conversion Shares to be approved for listing on the New York Stock Exchange. The Company shall use its commercially reasonable efforts to cause the Purchased Shares to be approved for listing on the New York Stock Exchange
as promptly as practicable after the date of this Agreement. 
 (c) Transfer Taxes. The Company shall pay any and all documentary,
stamp and similar issue or transfer tax incurred in connection with the issuance of the Purchased Shares pursuant to this Agreement. 
 (d)
Reservation of Shares. From and after the date of this Agreement, the Company will reserve shares of Common Stock from its authorized and unissued shares of Common Stock in such amount as may then be required to provide for all issuances of
shares of Common Stock under the Purchased Notes (the “Share Reserve”). The Company shall require its transfer agent to hold the shares of Common Stock reserved pursuant to the Share Reserve exclusively for the benefit of the
holder(s) of the Purchased Notes and to issue the corresponding shares of Common Stock to each such holder promptly upon such holder’s delivery of a conversion notice under a Purchased Note in accordance with the terms thereof. 

 

	 	7.	 MISCELLANEOUS. 

(a) Specific Performance. The parties hereto agree that irreparable damage could occur and that a party may not have any adequate
remedy at law in the event that any of the provisions of this Agreement are not performed in accordance with their terms or were otherwise breached. Accordingly, each party shall without the necessity of proving the inadequacy of money damages or
posting a bond be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms, provisions and covenants contained therein, this being in addition to any other remedy to which they are
entitled at law or in equity. 
 (b) Governing Law; Jurisdiction; Jury Trial. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY CHOICE OF LAW PROVISIONS WHICH WOULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION. BY ITS EXECUTION AND DELIVERY OF THIS AGREEMENT, EACH

  
 9 

 
PARTY IRREVOCABLY AND UNCONDITIONALLY AGREES FOR ITSELF THAT ANY LEGAL ACTION, SUIT, OR PROCEEDING AGAINST IT WITH RESPECT TO ANY MATTER ARISING UNDER OR ARISING OUT OF OR IN CONNECTION WITH THIS
AGREEMENT OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT RENDERED IN ANY SUCH ACTION, SUIT, OR PROCEEDING, MAY BE BROUGHT IN THE COURTS OF THE STATE OF NEW YORK LOCATED IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, OR OF THE UNITED STATES OF
AMERICA FOR THE SOUTHERN DISTRICT OF NEW YORK, AND BY EXECUTING AND DELIVERING THIS AGREEMENT, EACH OF THE PARTIES IRREVOCABLY ACCEPTS AND SUBMITS ITSELF TO THE EXCLUSIVE JURISDICTION OF SUCH COURT, GENERALLY AND UNCONDITIONALLY, WITH RESPECT TO ANY
SUCH ACTION, SUIT OR PROCEEDING. THE PARTIES HEREBY AGREE THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH ANY SUCH ACTION OR PROCEEDING TO AN ADDRESS PROVIDED IN WRITING BY THE RECIPIENT OF SUCH MAILING, OR IN SUCH OTHER MANNER AS MAY BE
PERMITTED BY LAW, SHALL BE VALID AND SUFFICIENT SERVICE THEREOF AND HEREBY WAIVE ANY OBJECTIONS TO SERVICE ACCOMPLISHED IN THE MANNER HEREIN PROVIDED. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT
IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. 

(c) Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the
same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile, .pdf or electronic (e.g., DocuSign) signature shall be considered due execution and shall be
binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile, .pdf or electronic signature. 

(d) Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement. 
 (e) Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be
invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the
invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable
provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). 

(f) Entire Agreement; Amendment and Waiver. This Agreement, the Registration Rights Agreement, the Purchased Notes and the Credit
Agreement contain the entire agreement by and among the parties with respect to the subject matter hereof and all prior negotiations, writings and understandings relating to the subject matter of this Agreement. This Agreement may not be modified or
amended except by an instrument or instruments in writing 

  
 10 

 
signed by each party hereto. Any party hereto may, only by an instrument in writing, waive compliance by any other party hereto with any term or provision hereof on the part of such other party
hereto to be performed or complied with. No failure or delay of any party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor will any single or partial exercise of any right or power, or any abandonment or
discontinuance of steps to enforce such right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The waiver by any party hereto of a breach of any term or provision hereof shall not be construed as
a waiver of any subsequent breach. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by law. 
 (g)
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered
personally; (ii) upon delivery, when sent by electronic mail; or (iii) one business day after deposit with an overnight courier service, in each case properly addressed to the party to receive the same. The addresses and e-mail addresses for such communications shall be: 
 If to the Company: 

Eastman Kodak Company 
 343
State Street 
 Rochester, New York 14650 

Attention: General Counsel 

Email:       roger.byrd@kodak.com 

with a copy (for informational purposes only) to: 

Sullivan & Cromwell LLP 

125 Broad Street 
 New York, New
York 10004 
 Attention: Neal McKnight 

Email:       McKnightN@sullcrom.com 

  
 11 

 If to the Buyers: 

Kennedy Lewis Capital Partners Master Fund LP 

Kennedy Lewis Capital Partners Master Fund II LP 

111 West 33rd Street, 19th Floor 

New York, New York 10001 

Attention: Anthony Pasqua     

Email: anthony.pasqua@klimllc.com>     

with a copy (for informational purposes only) to: 

Akin Gump Strauss Hauer & Feld LLP 

One Bryant Park 
 New York, NY
10036 
 Attention:    Daniel Fisher 

Email:         dfisher@akingump.com 

or to such other address and/or e-mail address and/or to the attention of such other Person as the recipient party has
specified by written notice given to each other party five (5) days prior to the effectiveness of such change. 

(h)    Successors and Assigns. The terms and conditions of this Agreement shall be binding upon and inure to the
benefit of the parties and their respective successors, heirs, and permitted assigns. Neither party shall assign this Agreement or any rights or obligations hereunder without the prior written consent of other party; provided that each Buyer may
assign its rights hereunder to its Affiliate(s). 
 (i)    No Third Party Beneficiaries. This Agreement is
intended solely for the benefit of the parties hereto and their respective successors, heirs and permitted assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 

(j)    Survival. Except in the case of intentional and actual fraud, the representations and warranties of the
parties contained in Section 4 and Section 5 hereof shall not survive, and shall terminate automatically as of, the Closing, and there shall be no liability in respect thereof, whether such
liability has accrued prior to or after the Closing, on the part of any party or any of their respective representatives. The covenants and agreements of the parties set forth in Section 6 and this
Section 7 shall survive the Closing in accordance with their terms. 
 (k)    Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. 

  
 12 

 (l) Interpretation. 

(i) When a reference is made in this Agreement to an Article, Section, Schedule or Exhibit, such reference shall be to an Article, Section,
Schedule or Exhibit of this Agreement unless otherwise indicated. 
 (ii) Whenever the words “include,” “includes” or
“including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” 
 (iii)
The words “hereof,” “herein,” and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole (including all of the Schedules and Exhibits) and not to any
particular provision of this Agreement. 
 (iv) The definitions contained in this Agreement are applicable to the singular as well as the
plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such term. 
 (v) Any agreement,
instrument or statute defined or referred to in this Agreement means such agreement, instrument or statute as from time to time amended, modified or supplemented, including (in the case of agreements or instruments) by waiver or consent and (in the
case of statutes) by succession of comparable successor statutes. 
 (vi) Each of the parties has participated in the drafting and
negotiation of this Agreement. If an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if it is drafted by each of the parties, and no presumption or burden of proof shall arise favoring or disfavoring
any party by virtue of authorship of any of the provisions of this Agreement. 
 (vii) As used in this Agreement,
“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any governmental entity or any department or agency
thereof. 
 (viii) As used in this Agreement, “Affiliate” of any Person means any other Person directly or
indirectly controlling or controlled by or under direct or indirect common control with such Person as of the date which, or at any time during the period for which, the determination of affiliation is being made. For purposes of this definition,
“control,” when used with respect to any Person, has the meaning specified in Rule 12b-2 under the Exchange Act; and the terms “controlling” and “controlled” have meanings
correlative to the foregoing. 
 [Signature Page Follows] 

  
 13 

 IN WITNESS WHEREOF, the Company and the Buyers have caused their respective signature
page to this Stock Purchase Agreement to be duly executed as of the date first written above. 
  

			
	COMPANY
	
	EASTMAN KODAK COMPANY
		
	 By:
	 	/s/ David E. Bullwinkle
		 	Name: David E. Bullwinkle
		 	Title: Chief Financial Officer and Senior Vice President

 [Signature Page to Securities Purchase Agreement] 

 
			
	BUYER
	
	KENNEDY LEWIS CAPITAL PARTNERS MASTER FUND LP
		
	 By:
	 	/s/ Anthony Pasqua
		 	Name: Anthony Pasqua
		 	Title: Authorized Signatory

 [Signature Page to Securities Purchase Agreement] 

 
			
	BUYER
	
	KENNEDY LEWIS CAPITAL PARTNERS MASTER FUND II LP
		
	 By:
	 	/s/ Anthony Pasqua
		 	Name: Anthony Pasqua
		 	Title: Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]